Pear Therapeutics, Inc. – NASDAQ:PEAR

Financial Health
0
1
2
3
4
5
6
7
8
9

Pear Therapeutics stock price monthly change

-82.88%
month

Pear Therapeutics stock price quarterly change

-99.52%
quarter

Pear Therapeutics stock price yearly change

-99.87%
year

Pear Therapeutics key metrics

Market Cap
4.08M
Enterprise value
N/A
P/E
-0.22
EV/Sales
-1.21
EV/EBITDA
0.16
Price/Sales
0.82
Price/Book
0.50
PEG ratio
0.01
EPS
0.16
Revenue
12.69M
EBITDA
-169.39M
Income
24.77M
Revenue Q/Q
-39.04%
Revenue Y/Y
201.66%
Profit margin
-501%
Oper. margin
-1018.74%
Gross margin
35.62%
EBIT margin
-1018.74%
EBITDA margin
-1334.48%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Pear Therapeutics stock price history

Pear Therapeutics stock forecast

Pear Therapeutics financial statements

Pear Therapeutics, Inc. (NASDAQ:PEAR): Profit margin
Mar 2022 2.74M -12.97M -472.06%
Jun 2022 3.29M 43.74M 1326.78%
Sep 2022 4.08M -34.81M -852.73%
Dec 2022 2.56M 28.82M 1123.86%
Pear Therapeutics, Inc. (NASDAQ:PEAR): Debt to assets
Mar 2022 172092000 102.58M 59.61%
Jun 2022 142519000 63.47M 44.54%
Sep 2022 119735000 67.48M 56.37%
Dec 2022 95129000 64.54M 67.85%
Pear Therapeutics, Inc. (NASDAQ:PEAR): Cash Flow
Mar 2022 -36.70M -43.5M 75K
Jun 2022 -29.63M -307K 761K
Sep 2022 -23.27M 22.42M 358K
Dec 2022 -24.28M 11.93M 961K

Pear Therapeutics alternative data

Pear Therapeutics, Inc. (NASDAQ:PEAR): Employee count
Aug 2023 200
Sep 2023 200
Oct 2023 200
Nov 2023 200
Dec 2023 200
Jan 2024 200
Feb 2024 200
Mar 2024 200
Apr 2024 200
May 2024 200
Jun 2024 200
Jul 2024 200

Pear Therapeutics other data

Pear Therapeutics, Inc. (NASDAQ:PEAR): Insider trades (number of shares)
Period Buy Sel
Aug 2022 0 400000
Sep 2022 0 1328168
Oct 2022 0 42164
Nov 2022 0 117326
Jan 2023 0 115096
Apr 2023 0 3707624
Transaction Date Insider Security Shares Price per share Total value Source
Sale
5AM PARTNERS IV, LLC 10 percent owner
Class A Common Stock 534,855 $0.12 $64,183
Sale
5AM PARTNERS IV, LLC 10 percent owner
Class A Common Stock 3,172,769 $0.12 $380,732
Sale
O'BRIEN RONAN officer: GC, CCO & Secretary
Class A Common Stock 12,162 $1.13 $13,743
Sale
SNOW ELLEN officer: Chief Accounting Officer
Class A Common Stock 8,027 $1.13 $9,071
Sale
STRANDBERG JULIA officer: Chief Commercial Officer
Class A Common Stock 12,688 $1.13 $14,337
Sale
BRENNER ERIN K. officer: Chief Product Dev. Off..
Class A Common Stock 8,690 $1.13 $9,820
Sale
GUIFFRE CHRISTOPHERD T officer: CFO, COO, Treas., & As..
Class A Common Stock 19,540 $1.13 $22,080
Sale
JEFFERY KATHERINE officer: Chief People Officer
Class A Common Stock 7,096 $1.13 $8,018
Sale
MARICICH YURI officer: Chief Medical Officer
Class A Common Stock 12,162 $1.13 $13,743
Sale
MCCANN COREY officer: President and CEO
Class A Common Stock 34,731 $1.13 $39,246
Friday, 14 April 2023
InvestorPlace
Tuesday, 21 March 2023
InvestorPlace
Thursday, 19 January 2023
Zacks Investment Research
Thursday, 17 November 2022
Seeking Alpha
Monday, 14 November 2022
Seeking Alpha
Thursday, 18 August 2022
Seeking Alpha
Sunday, 14 August 2022
Seeking Alpha
Wednesday, 10 August 2022
Zacks Investment Research
Tuesday, 24 May 2022
PennyStocks
Saturday, 21 May 2022
Seeking Alpha
Tuesday, 17 May 2022
Seeking Alpha
Monday, 18 April 2022
Business Wire
Monday, 4 April 2022
Seeking Alpha
Monday, 28 March 2022
Seeking Alpha
Tuesday, 15 March 2022
Benzinga
Monday, 10 January 2022
Seeking Alpha
Monday, 3 January 2022
Invezz
Benzinga
Saturday, 1 January 2022
24/7 Wall Street
  • When is Pear Therapeutics's next earnings date?

    Unfortunately, Pear Therapeutics's (PEAR) next earnings date is currently unknown.

  • Does Pear Therapeutics pay dividends?

    No, Pear Therapeutics does not pay dividends.

  • How much money does Pear Therapeutics make?

    Pear Therapeutics has a market capitalization of 4.08M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 201.66% to 12.69M US dollars.

  • What is Pear Therapeutics's stock symbol?

    Pear Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PEAR".

  • What is Pear Therapeutics's primary industry?

    Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.

  • How do i buy shares of Pear Therapeutics?

    Shares of Pear Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Pear Therapeutics have?

    As Jul 2024, Pear Therapeutics employs 200 workers.

  • When Pear Therapeutics went public?

    Pear Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 31 Mar 2021.

  • What is Pear Therapeutics's official website?

    The official website for Pear Therapeutics is peartherapeutics.com.

  • Where are Pear Therapeutics's headquarters?

    Pear Therapeutics is headquartered at 200 State Street, Boston, MA.

  • How can i contact Pear Therapeutics?

    Pear Therapeutics's mailing address is 200 State Street, Boston, MA and company can be reached via phone at +61 79257848.

Pear Therapeutics company profile:

Pear Therapeutics, Inc.

peartherapeutics.com
Exchange:

NASDAQ

Full time employees:

200

Industry:

Medical - Healthcare Information Services

Sector:

Healthcare

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

200 State Street
Boston, MA 02109

CIK: 0001835567
ISIN: US7047231052
CUSIP: 704723105